Sign In
Buy LNTH
Lantheus Holdings Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | $1.25 |
| EPS actual | $1.46 |
| EPS Surprise | 16.80% |
| Revenue estimate | 354.476M |
| Revenue actual | 377.333M |
| Revenue Surprise | 6.45% |
| Release date | Feb 26, 2026 |
| EPS estimate | $1.18 |
| EPS actual | $1.67 |
| EPS Surprise | 41.53% |
| Revenue estimate | 366.995M |
| Revenue actual | 406.786M |
| Revenue Surprise | 10.84% |
| Release date | Nov 06, 2025 |
| EPS estimate | $1.27 |
| EPS actual | $1.27 |
| Revenue estimate | 367.985M |
| Revenue actual | 384.014M |
| Revenue Surprise | 4.36% |
| Release date | Aug 06, 2025 |
| EPS estimate | $1.64 |
| EPS actual | $1.57 |
| EPS Surprise | -4.27% |
| Revenue estimate | 363.338M |
| Revenue actual | 378.045M |
| Revenue Surprise | 4.05% |
Last 4 Quarters for Lantheus Holdings
Below you can see how LNTH performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $51.87 |
| EPS estimate | $1.64 |
| EPS actual | $1.57 |
| EPS surprise | -4.27% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $71.19 |
| Aug 01, 2025 | $70.57 |
| Aug 04, 2025 | $71.46 |
| Aug 05, 2025 | $72.63 |
| Aug 06, 2025 | $51.87 |
| Aug 07, 2025 | $54.86 |
| Aug 08, 2025 | $57.20 |
| Aug 11, 2025 | $56.07 |
| Aug 12, 2025 | $53.90 |
| 4 days before | -27.14% |
| 4 days after | 3.91% |
| On release day | 5.76% |
| Change in period | -24.29% |
| Release date | Nov 06, 2025 |
| Price on release | $53.69 |
| EPS estimate | $1.27 |
| EPS actual | $1.27 |
| Date | Price |
|---|---|
| Oct 31, 2025 | $57.69 |
| Nov 03, 2025 | $56.82 |
| Nov 04, 2025 | $57.71 |
| Nov 05, 2025 | $57.23 |
| Nov 06, 2025 | $53.69 |
| Nov 07, 2025 | $51.07 |
| Nov 10, 2025 | $50.69 |
| Nov 11, 2025 | $53.37 |
| Nov 12, 2025 | $54.50 |
| 4 days before | -6.93% |
| 4 days after | 1.51% |
| On release day | -4.88% |
| Change in period | -5.53% |
| Release date | Feb 26, 2026 |
| Price on release | $75.43 |
| EPS estimate | $1.18 |
| EPS actual | $1.67 |
| EPS surprise | 41.53% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $73.87 |
| Feb 23, 2026 | $73.42 |
| Feb 24, 2026 | $73.61 |
| Feb 25, 2026 | $75.72 |
| Feb 26, 2026 | $75.43 |
| Feb 27, 2026 | $74.91 |
| Mar 02, 2026 | $76.30 |
| Mar 03, 2026 | $78.84 |
| Mar 04, 2026 | $77.84 |
| 4 days before | 2.11% |
| 4 days after | 3.20% |
| On release day | -0.689% |
| Change in period | 5.37% |
| Release date | May 07, 2026 |
| Price on release | $91.00 |
| EPS estimate | $1.25 |
| EPS actual | $1.46 |
| EPS surprise | 16.80% |
| Date | Price |
|---|---|
| May 01, 2026 | $85.50 |
| May 04, 2026 | $87.78 |
| May 05, 2026 | $85.82 |
| May 06, 2026 | $86.15 |
| May 07, 2026 | $91.00 |
| May 08, 2026 | $93.06 |
| May 11, 2026 | $94.07 |
| May 12, 2026 | $96.23 |
| May 13, 2026 | $96.46 |
| 4 days before | 6.43% |
| 4 days after | 6.00% |
| On release day | 2.26% |
| Change in period | 12.82% |
Lantheus Holdings Earnings Call Transcript Summary of Q1 2026
Lantheus delivered a solid start to 2026 with Q1 revenue of $377.3M (up 1.2% YoY, +8.6% ex-divestiture) and adjusted EPS of $1.46. Commercial performance was led by NEUROCEQ (Q1 revenue $35.4M, +14.3% sequentially) and DEFINITY ($84.6M, +6.8% YoY); PYLARIFY remains the core oncology franchise with U.S. volume +5.8% YoY but oncology revenue was down YoY to $240.9M. Key regulatory and pipeline milestones: FDA approved PYLARIFY TRUVU (new PSMA PET formulation) with conversions planned to begin in Q4 2026; PNT2003 (a Lutathera equivalent) received tentative FDA approval; Actinium’s PDUFA was extended to June 29, 2026; MK-6240 (tau PET) has a PDUFA of August 13, 2026. Management reiterated full-year 2026 guidance: revenue $1.40–$1.45B and adjusted EPS $5.00–$5.25, citing prudence given competitive dynamics and an upcoming CEO transition. Operational highlights: gross margin ~67%, operating profit $129.1M, operating cash flow $125.1M, free cash flow $121.9M, cash and equivalents ~$498.6M, $200M remaining on buyback authorization and a $750M undrawn revolver. Strategic focus remains on radio diagnostics (protecting PSMA franchise, scaling TRUVU, expanding NEUROCEQ footprint and manufacturing capacity) while evaluating value-maximizing alternatives for therapeutic/radiotherapeutic assets. Management expects 2027 to be a year of growth acceleration once TRUVU conversion, coding/reimbursement and other launch readiness elements are in place.
